EE200000614A - Polüool-IFN-ß konjugaat, selle valmistamismeetod,farmatseutiline kompositsioon ja selle kasutaminening meetod polüetüleenglükooli jääkide kinnitamiseks polüpeptiidile ja PEG-polüpeptiidi konjugaadikasutamine - Google Patents
Polüool-IFN-ß konjugaat, selle valmistamismeetod,farmatseutiline kompositsioon ja selle kasutaminening meetod polüetüleenglükooli jääkide kinnitamiseks polüpeptiidile ja PEG-polüpeptiidi konjugaadikasutamineInfo
- Publication number
- EE200000614A EE200000614A EEP200000614A EEP200000614A EE200000614A EE 200000614 A EE200000614 A EE 200000614A EE P200000614 A EEP200000614 A EE P200000614A EE P200000614 A EEP200000614 A EE P200000614A EE 200000614 A EE200000614 A EE 200000614A
- Authority
- EE
- Estonia
- Prior art keywords
- conjugate
- polypeptide
- ifn
- polyol
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8333998P | 1998-04-28 | 1998-04-28 | |
PCT/US1999/009161 WO1999055377A2 (en) | 1998-04-28 | 1999-04-28 | Polyol-ifn-beta conjugates |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200000614A true EE200000614A (et) | 2002-04-15 |
EE05214B1 EE05214B1 (et) | 2009-10-15 |
Family
ID=22177687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200000614A EE05214B1 (et) | 1998-04-28 | 1999-04-28 | Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon |
Country Status (31)
Country | Link |
---|---|
US (3) | US6638500B1 (et) |
EP (2) | EP1421956B1 (et) |
JP (2) | JP4574007B2 (et) |
KR (1) | KR100622796B1 (et) |
CN (2) | CN1187094C (et) |
AR (1) | AR020070A1 (et) |
AT (2) | ATE365563T1 (et) |
AU (1) | AU762621B2 (et) |
BG (2) | BG64694B1 (et) |
BR (1) | BR9910023A (et) |
CA (2) | CA2330451A1 (et) |
CY (1) | CY1108022T1 (et) |
CZ (2) | CZ298579B6 (et) |
DE (2) | DE69920002T2 (et) |
DK (2) | DK1421956T3 (et) |
EA (2) | EA200300382A1 (et) |
EE (1) | EE05214B1 (et) |
ES (2) | ES2285286T3 (et) |
HK (2) | HK1038194A1 (et) |
HU (1) | HUP0300548A3 (et) |
IL (1) | IL139286A (et) |
NO (2) | NO329749B1 (et) |
NZ (1) | NZ507456A (et) |
PL (2) | PL196533B1 (et) |
PT (2) | PT1075281E (et) |
SI (2) | SI1421956T1 (et) |
SK (2) | SK286654B6 (et) |
TR (2) | TR200003161T2 (et) |
TW (2) | TWI266800B (et) |
UA (2) | UA66857C2 (et) |
WO (1) | WO1999055377A2 (et) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
EP1121382B9 (en) | 1998-10-16 | 2007-07-04 | Biogen Idec MA Inc. | Interferon-beta fusion proteins and uses |
NZ510689A (en) * | 1998-10-16 | 2003-07-25 | Biogen Inc | Polymer conjugates of interferon beta-1a and uses |
EP1880736A1 (en) * | 1999-04-23 | 2008-01-23 | Alza Corporation | Releasable linkage and composition containing same |
US7303760B2 (en) * | 1999-04-23 | 2007-12-04 | Alza Corporation | Method for treating multi-drug resistant tumors |
US7238368B2 (en) * | 1999-04-23 | 2007-07-03 | Alza Corporation | Releasable linkage and compositions containing same |
US6531122B1 (en) | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
US7431921B2 (en) | 2000-04-14 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
US7144574B2 (en) | 1999-08-27 | 2006-12-05 | Maxygen Aps | Interferon β variants and conjugates |
TR200101086A3 (et) * | 1999-10-15 | 2001-08-21 | ||
WO2001048052A1 (fr) | 1999-12-24 | 2001-07-05 | Kyowa Hakko Kogyo Co., Ltd. | Glycols de polyalkylene ramifies |
KR100773323B1 (ko) | 2000-01-10 | 2007-11-05 | 맥시겐 홀딩스 리미티드 | 지-씨에스에프 접합체 |
CA2397347C (en) | 2000-02-11 | 2011-07-12 | Maxygen Aps | Factor vii or viia-like molecules |
CA2436623C (en) | 2001-01-30 | 2011-08-02 | Kyowa Hakko Kogyo Co., Ltd. | Branched polyalkylene glycols |
EP1234583A1 (en) * | 2001-02-23 | 2002-08-28 | F. Hoffmann-La Roche Ag | PEG-conjugates of HGF-NK4 |
WO2002074806A2 (en) | 2001-02-27 | 2002-09-26 | Maxygen Aps | New interferon beta-like molecules |
WO2003006501A2 (en) | 2001-07-11 | 2003-01-23 | Maxygen Holdings, Ltd. | G-csf conjugates |
ES2774801T3 (es) | 2002-01-18 | 2020-07-22 | Biogen Ma Inc | Compuestos de polímero de polialquileno y usos de los mismos |
TWI334785B (en) | 2002-06-03 | 2010-12-21 | Serono Lab | Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race |
AU2003254641A1 (en) * | 2002-08-28 | 2004-03-19 | Maxygen Aps | Interferon beta-like molecules for treatment of cancer |
US8129330B2 (en) * | 2002-09-30 | 2012-03-06 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
WO2004060300A2 (en) * | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
CA2511814C (en) * | 2002-12-26 | 2015-02-17 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of interferon-beta with enhanced biological potency |
AU2004221761B2 (en) | 2003-03-20 | 2010-01-07 | Bayer Healthcare Llc | FVII or FVIIa variants |
TWI272948B (en) | 2003-05-01 | 2007-02-11 | Ares Trading Sa | HSA-free stabilized interferon liquid formulations |
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
ES2428358T3 (es) | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
AU2005209926B2 (en) * | 2004-02-02 | 2007-09-06 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
AU2008201682B2 (en) * | 2004-02-02 | 2011-02-24 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
EP1586334A1 (en) * | 2004-04-15 | 2005-10-19 | TRASTEC scpa | G-CSF conjugates with peg |
ZA200609412B (en) | 2004-05-17 | 2008-07-30 | Ares Trading Sa | Hydrogel interferon formulations |
EA012281B1 (ru) | 2004-06-01 | 2009-08-28 | Арес Трейдинг С.А. | Способ стабилизации белков |
CN1993139B (zh) | 2004-06-01 | 2011-02-16 | 阿雷斯贸易股份有限公司 | 稳定的干扰素液体制剂 |
TW200633718A (en) * | 2004-12-16 | 2006-10-01 | Applied Research Systems | Treatment of hepatitis c in the asian population |
MX2007007471A (es) | 2004-12-21 | 2007-07-20 | Nektar Therapeutics Al Corp | Reactivos de tiol polimericos estabilizados. |
MX2007007591A (es) | 2004-12-22 | 2007-07-25 | Ambrx Inc | Metodos para expresion y purificacion de hormona de crecimiento humano recombinante. |
NZ555386A (en) | 2004-12-22 | 2011-01-28 | Ambrx Inc | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
EP2284191A3 (en) | 2004-12-22 | 2011-07-20 | Ambrx, Inc. | Process for the preparation of hGH |
US8633300B2 (en) | 2005-06-17 | 2014-01-21 | Novo Nordisk Healthcare Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
KR20080033439A (ko) * | 2005-08-04 | 2008-04-16 | 넥타르 테라퓨틱스 에이엘, 코포레이션 | G-csf 부분 및 중합체의 컨주게이트 |
DK1917276T3 (en) | 2005-08-26 | 2018-05-07 | Ares Trading Sa | Process for Preparation of Glycosylated Interferon Beta |
WO2007025991A2 (en) | 2005-09-01 | 2007-03-08 | Ares Trading S.A. | Treatment of optic neuritis |
US20070238656A1 (en) * | 2006-04-10 | 2007-10-11 | Eastman Kodak Company | Functionalized poly(ethylene glycol) |
US20080096819A1 (en) * | 2006-05-02 | 2008-04-24 | Allozyne, Inc. | Amino acid substituted molecules |
EP2018437A2 (en) * | 2006-05-02 | 2009-01-28 | Allozyne, Inc. | Non-natural amino acid substituted polypeptides |
US9925151B2 (en) | 2006-05-24 | 2018-03-27 | Merck Serono Sa | Cladribine regimen for treating multiple sclerosis |
AU2007253264A1 (en) | 2006-05-24 | 2007-11-29 | Novo Nordisk Health Care Ag | Factor IX analogues having prolonged in vivo half life |
WO2008137471A2 (en) | 2007-05-02 | 2008-11-13 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
CA2707840A1 (en) * | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
PL2234645T3 (pl) * | 2007-12-20 | 2012-10-31 | Merck Serono Sa | Preparaty interferonu-beta modyfikowanego PEG |
CN101939443B (zh) | 2008-02-08 | 2014-01-29 | Ambrx公司 | 经修饰瘦素多肽和其用途 |
CN101525381B (zh) * | 2008-03-04 | 2012-04-18 | 北京百川飞虹生物科技有限公司 | 一种重组复合干扰素及其表达载体的构建和表达 |
WO2009155102A2 (en) * | 2008-05-30 | 2009-12-23 | Barofold, Inc. | Method for derivatization of proteins using hydrostatic pressure |
US20110124614A1 (en) * | 2008-10-25 | 2011-05-26 | Halina Offner | Methods And Compositions For The Treatment of Autoimmune Disorders |
DE102009032179A1 (de) * | 2009-07-07 | 2011-01-13 | Biogenerix Ag | Verfahren zur Reinigung von Interferon beta |
ES2365343B1 (es) | 2009-11-19 | 2012-07-10 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de cd98 como marcador de receptividad endometrial. |
EP2536753B1 (en) | 2010-02-16 | 2017-12-20 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
AR080993A1 (es) | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
WO2011143274A1 (en) | 2010-05-10 | 2011-11-17 | Perseid Therapeutics | Polypeptide inhibitors of vla4 |
US20130183280A1 (en) | 2010-07-15 | 2013-07-18 | Novo Nordisk A/S | Stabilized factor viii variants |
JP6042335B2 (ja) | 2010-09-15 | 2016-12-14 | ノヴォ ノルディスク アー/エス | 細胞取込みが低下した第viii因子変異体 |
EP3395356B1 (en) * | 2011-02-18 | 2021-05-19 | Stemdr Inc. | Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock |
JP2014522641A (ja) | 2011-07-01 | 2014-09-08 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | リラキシン融合ポリペプチドおよびその使用 |
BR112014007766B1 (pt) * | 2011-10-01 | 2022-05-10 | Glytech, Inc | Polipeptídeo glicosilado, método para fabricação do mesmo e composição farmacêutica |
SG10201700340WA (en) | 2012-02-27 | 2017-03-30 | Amunix Operating Inc | Xten conjugate compositions and methods of making same |
MX2014010209A (es) | 2012-02-29 | 2014-11-21 | Toray Industries | Agente inhibidor para acumulacion de fluido de la cavidad corporal. |
SG11201507769SA (en) | 2013-03-29 | 2015-10-29 | Glytech Inc | Polypeptide having sialylated sugar chains attached thereto |
WO2016013911A1 (ko) * | 2014-07-24 | 2016-01-28 | 에이비온 주식회사 | 페길화된 인터페론 -베타 변이체 |
WO2016013697A1 (ko) * | 2014-07-24 | 2016-01-28 | 에이비온 주식회사 | 인터페론-베타 변이체의 폴리에틸렌글리콜 배합체 |
WO2017030563A1 (en) | 2014-08-19 | 2017-02-23 | Biogen Ma Inc | Pegylation method |
ES2903448T3 (es) | 2015-05-01 | 2022-04-01 | Allysta Pharmaceuticals Inc | Peptidomiméticos de adiponectina para el tratamiento de trastornos oculares |
MX2017016674A (es) * | 2015-06-19 | 2018-08-01 | Eisai R&D Man Co Ltd | Inmunoglobulinas conjugadas en cys80. |
CN110753556A (zh) * | 2017-04-17 | 2020-02-04 | 科罗拉多州立大学董事会法人团体 | 治疗同型半胱氨酸尿症的酶替代疗法优化 |
WO2020158690A1 (ja) | 2019-01-28 | 2020-08-06 | 東レ株式会社 | 肝細胞増殖因子又はその活性断片のポリエチレングリコール修飾体 |
CA3124682A1 (en) | 2019-01-28 | 2020-08-06 | Toray Industries, Inc. | Polyethylene glycol-modified form of hepatocyte growth factor or active fragment thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
EP0229108B1 (en) * | 1985-06-26 | 1990-12-27 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US5206344A (en) * | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
US5208344A (en) * | 1987-07-31 | 1993-05-04 | American Home Products Corporation | Naphthalenepropionic acid derivatives as anti-inflammatory/antiallergic agents |
US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
US5595732A (en) * | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
KR960705579A (ko) | 1993-11-10 | 1996-11-08 | 에릭에스. 딕커 | 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates) |
CA2167090C (en) * | 1994-03-31 | 2002-05-14 | Timothy D. Bartley | Compositions and methods for stimulating megakaryocyte growth and differentiation |
ATE299892T1 (de) * | 1994-05-18 | 2005-08-15 | Nektar Therapeutics | Methoden und zusammensetzungen für die trockenpuderarznei aus interferonen |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
SE9503380D0 (sv) * | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
US5851984A (en) * | 1996-08-16 | 1998-12-22 | Genentech, Inc. | Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides |
KR0176625B1 (ko) | 1996-11-05 | 1999-04-01 | 삼성전자주식회사 | 적외선 물체검출장치 |
AU5773798A (en) * | 1997-01-29 | 1998-08-18 | Polymasc Pharmaceuticals Plc | Pegylation process |
WO1999003887A1 (en) * | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
US6531122B1 (en) * | 1999-08-27 | 2003-03-11 | Maxygen Aps | Interferon-β variants and conjugates |
-
1999
- 1999-04-28 NZ NZ507456A patent/NZ507456A/en not_active IP Right Cessation
- 1999-04-28 DK DK04003053T patent/DK1421956T3/da active
- 1999-04-28 AT AT04003053T patent/ATE365563T1/de active
- 1999-04-28 CZ CZ20003995A patent/CZ298579B6/cs not_active IP Right Cessation
- 1999-04-28 IL IL13928699A patent/IL139286A/xx not_active IP Right Cessation
- 1999-04-28 UA UA2000116719A patent/UA66857C2/uk unknown
- 1999-04-28 PT PT99920094T patent/PT1075281E/pt unknown
- 1999-04-28 SK SK66-2007A patent/SK286654B6/sk not_active IP Right Cessation
- 1999-04-28 KR KR1020007011587A patent/KR100622796B1/ko not_active IP Right Cessation
- 1999-04-28 TR TR2000/03161T patent/TR200003161T2/xx unknown
- 1999-04-28 PL PL378728A patent/PL196533B1/pl not_active IP Right Cessation
- 1999-04-28 TR TR2001/01751T patent/TR200101751T2/xx unknown
- 1999-04-28 EP EP04003053A patent/EP1421956B1/en not_active Expired - Lifetime
- 1999-04-28 BR BR9910023-1A patent/BR9910023A/pt active Search and Examination
- 1999-04-28 EA EA200300382A patent/EA200300382A1/ru not_active IP Right Cessation
- 1999-04-28 WO PCT/US1999/009161 patent/WO1999055377A2/en active IP Right Grant
- 1999-04-28 DE DE69920002T patent/DE69920002T2/de not_active Expired - Lifetime
- 1999-04-28 CA CA002330451A patent/CA2330451A1/en not_active Abandoned
- 1999-04-28 CN CNB998054968A patent/CN1187094C/zh not_active Expired - Fee Related
- 1999-04-28 AT AT99920094T patent/ATE275422T1/de active
- 1999-04-28 PL PL344490A patent/PL193352B1/pl not_active IP Right Cessation
- 1999-04-28 AU AU37674/99A patent/AU762621B2/en not_active Ceased
- 1999-04-28 EP EP99920094A patent/EP1075281B1/en not_active Expired - Lifetime
- 1999-04-28 EE EEP200000614A patent/EE05214B1/et not_active IP Right Cessation
- 1999-04-28 SI SI9930974T patent/SI1421956T1/sl unknown
- 1999-04-28 CZ CZ20050048A patent/CZ298597B6/cs not_active IP Right Cessation
- 1999-04-28 SI SI9930662T patent/SI1075281T1/xx unknown
- 1999-04-28 DK DK99920094T patent/DK1075281T3/da active
- 1999-04-28 UA UA20031212655A patent/UA79430C2/uk unknown
- 1999-04-28 DE DE69936409T patent/DE69936409T2/de not_active Expired - Lifetime
- 1999-04-28 JP JP2000545574A patent/JP4574007B2/ja not_active Expired - Lifetime
- 1999-04-28 SK SK1622-2000A patent/SK286217B6/sk not_active IP Right Cessation
- 1999-04-28 CA CA002565375A patent/CA2565375A1/en not_active Abandoned
- 1999-04-28 ES ES04003053T patent/ES2285286T3/es not_active Expired - Lifetime
- 1999-04-28 EA EA200001111A patent/EA003789B1/ru not_active IP Right Cessation
- 1999-04-28 HU HU0300548A patent/HUP0300548A3/hu unknown
- 1999-04-28 PT PT04003053T patent/PT1421956E/pt unknown
- 1999-04-28 ES ES99920094T patent/ES2224649T3/es not_active Expired - Lifetime
- 1999-04-28 CN CNB2004100898478A patent/CN100335503C/zh not_active Expired - Fee Related
- 1999-04-29 AR ARP990101987A patent/AR020070A1/es active IP Right Grant
- 1999-07-26 TW TW093123043A patent/TWI266800B/zh active
- 1999-07-26 TW TW088112596A patent/TWI232882B/zh active
-
2000
- 2000-10-17 BG BG104871A patent/BG64694B1/bg unknown
- 2000-10-17 BG BG109291A patent/BG65046B1/bg unknown
- 2000-10-23 NO NO20005337A patent/NO329749B1/no not_active IP Right Cessation
- 2000-10-30 US US09/698,133 patent/US6638500B1/en not_active Expired - Lifetime
-
2001
- 2001-12-24 HK HK01109037A patent/HK1038194A1/xx not_active IP Right Cessation
-
2003
- 2003-08-28 US US10/649,609 patent/US7357925B2/en not_active Expired - Fee Related
-
2005
- 2005-11-17 HK HK05110273A patent/HK1076115A1/xx not_active IP Right Cessation
-
2007
- 2007-02-13 US US11/674,476 patent/US7700314B2/en not_active Expired - Fee Related
- 2007-07-19 CY CY20071100966T patent/CY1108022T1/el unknown
-
2010
- 2010-03-09 NO NO20100324A patent/NO332224B1/no not_active IP Right Cessation
- 2010-04-26 JP JP2010100840A patent/JP2010184929A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200000614A (et) | Polüool-IFN-ß konjugaat, selle valmistamismeetod,farmatseutiline kompositsioon ja selle kasutaminening meetod polüetüleenglükooli jääkide kinnitamiseks polüpeptiidile ja PEG-polüpeptiidi konjugaadikasutamine | |
EE9800136A (et) | Depooravimiks sobiv farmatseutiline kompositsioon, selle valmistamismeetod ja kasutamine | |
EE9800180A (et) | Gonadotropiini riliisinghormooni antagonist, selle kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod | |
EE9800181A (et) | Gonadotropiini riliisinghormooni antagonist, selle kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod | |
EE04042B1 (et) | Suure bioomastatavusega fenofibraatide ravimkoostis ja meetod selle valmistamiseks | |
NO20004741D0 (no) | Farmasøytiske blandinger for forlenget peptidfrigjøring og fremstillingsmetode | |
EE200000319A (et) | hGRF-PEG konjugaatide saitspetsiifiline valmistamismeetod, hGRF-PEG konjugaadid, nende vaheühendid, kasutamine ja farmatseutiline kompositsioon | |
EE05021B1 (et) | Enterokattega ravimkoostis ja selle valmistamise meetod | |
EE04926B1 (et) | Enterokattega ravimkoostis ja selle valmistamise meetod | |
BR9709267A (pt) | Preparação de anticorpo monoclonal para administração a um humano formulação farmacêutica uso de uma preparação de anticorpo monoclonal e processo para a fabricação de uma preparação de anticorpo monoclonal | |
EE04417B1 (et) | Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm, selle valmistamise meetod ja kasutamine | |
EE200100684A (et) | Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid | |
ITMI950529A0 (it) | Composizioni farmaceutiche e procedimento per la loro preparazione | |
EE9500064A (et) | Asendatud 1H-imidasoolid, nende valmistamismeetodid ja farmatseutilised kompositsioonid | |
EE200000225A (et) | Arüüloksüalküüldialküülamiinid, nende valmistamismeetodid ja farmatseutiline kompositsioon | |
HK1061841A1 (en) | Cyclic amino acids and derivatives thereof useful as pharmaceutical agents | |
EE9900112A (et) | 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid | |
EE04119B1 (et) | Külmkuivatamiseks sobiv ravimkoostis ja selle valmistamise meetod | |
EE04681B1 (et) | 3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon | |
IT1287174B1 (it) | Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono | |
EE03554B1 (et) | Mikropoorne kristalne materjal, selle valmistamismeetod ja kasutamine detergentkompositsioonides | |
EE200100706A (et) | A-grupi streptogramiinide derivaadid, nende valmistamismeetod ja farmatseutiline kompositsioon | |
EE9900034A (et) | Arüültsükloalkaankarboksüülestrid, nende kasutamine, farmatseutilised kompositsioonid ja valmistamine | |
EE03996B1 (et) | Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine | |
EE04770B1 (et) | Tritsüklilised delta3-piperidiinid, nende valmistamismeetod, kasutamine, farmatseutiline kompositsioon ja selle valmistamismeetod |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB1A | Change in the ownership or in the address of the owner | ||
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
HC1A | Change of owner name | ||
MM4A | Lapsed by not paying the annual fees |
Effective date: 20130428 |